The antihypertensive drug angiotensin II receptor inhibitor losartan inhibited liver and peritumoral fibrosis, thereby substantially boosting tumor regression induced by anti-PD-1 therapy, mostly by facilitating effector CD8+ T-cell-mediated infiltration. The gene discussed is CD8A; the disease is neoplasm.